Merck & Co. Inc. (MRK) shares have a $108 price target

　　Merck is one of the world's largest pharmaceutical companies, and its leading products include cancer drug Keytruda and HPV vaccine Gardasil. Hardy says the post-election weakness in Merck's stock is a buying opportunity for long-term investors. He says Merck has been hit particularly hard following the nomination of vaccine critic Robert F. Kennedy Jr. as secretary of the Health and Human Services Department. However, Hardy says Merck is well diversified outside of vaccines, including a strong presence in immunology, oncology, diabetes, cardiovascular disease and animal health. CFRA has a "buy" rating and $108 price target for MRK stock, which closed at $101.85 on Dec. 3.